Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung

Autor: Kenneth J. Hampel, Nikoletta Sidiropoulos, Farrah Khan, Agnes Balla, Dara L. Aisner
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Adult
Lung Neoplasms
Oncogene Proteins
Fusion
medicine.medical_treatment
Biopsy
Targeted therapy
03 medical and health sciences
0302 clinical medicine
hemic and lymphatic diseases
Carcinoma
Non-Small-Cell Lung
medicine
Adenocarcinoma of the lung
Anaplastic lymphoma kinase
Humans
Anaplastic Lymphoma Kinase
Epidermal growth factor receptor
Molecular Targeted Therapy
Neoplasm Metastasis
neoplasm of the lung
Protein Kinase Inhibitors
Chromosomal inversion
Neoplasm Staging
Gene Rearrangement
biology
Oncogene
business.industry
General Medicine
Exons
medicine.disease
respiratory tract diseases
030104 developmental biology
Cell Transformation
Neoplastic
030220 oncology & carcinogenesis
Cancer research
biology.protein
Adenocarcinoma
Female
business
Tomography
X-Ray Computed
Tyrosine kinase
Rapid Cancer Communication
Zdroj: Cold Spring Harbor Molecular Case Studies
ISSN: 2373-2873
Popis: Anaplastic lymphoma kinase (ALK) gene rearrangements are present in ∼5% of non-small-cell lung cancers (NSCLCs). These rearrangements occur because of a chromosomal inversion within the short arm of Chromosome 2, which results in the formation of the echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion oncogene. Whereas NSCLC transformation to SCLC is a rare phenomenon described in epidermal growth factor receptor (EGFR) mutant cancers primarily after treatment with targeted therapy, it is exceedingly rare in ALK-rearranged adenocarcinomas. It is currently unclear what the therapeutic significance of the rearrangement is in this transformed tumor as there is a paucity of medical literature describing follow-up care and outcomes of patients in this rare scenario. We describe a unique case in which a patient with ALK-rearranged adenocarcinoma underwent small-cell transformation at a metastatic site with retained ALK rearrangement and was provided clinical follow-up after treatment with second-generation tyrosine kinase inhibiter (TKI) therapy.
Databáze: OpenAIRE
Externí odkaz: